Development of a target-capture NGS assay for use in molecular-based research of myeloid measurable residual disease (MRD)

Contributors

Natalie Milner, Giulia Poloni, James Reid, Venu Pullabhatla, Lyudmila Georgieva, Graham Speight (Oxford Gene Technology)

Introduction

Molecular methods are increasingly supporting traditional immunophenotypic multiparameter flow cytometry (MFC) in detection of measurable residual disease (MRD), including acute myeloid leukaemia (AML).

Real-time qPCR (RQ-PCR) and digital droplet PCR (ddPCR) are highly sensitive technologies but are limited by the number of targets that can be detected in one assay.

Next-generation sequencing (NGS) offers the opportunity to evaluate many genes in a single assay. Improved accuracy together with falling costs are facilitating the use of NGS in MRD.

We have developed a target-capture NGS approach to support researchers in studies of molecular-based MRD monitoring in myeloid malignancies.

This method provides the opportunity to evaluate many genes and variant types in a single assay.